|
|
||||||||

* Department of Pathology and
Division of Infectious Disease, Case Western Reserve University, Cleveland, OH 44106
Class II transactivator (CIITA) is necessary for expression of
class II MHC (MHC-II) molecules. In mice, CIITA expression is regulated
by three promoters (pI, pIII, and pIV), producing types I, III, and IV
CIITA. The relative roles of different CIITA types remain unclear.
Unstimulated bone marrow-derived macrophages expressed low levels of
CIITA mRNA; type I CIITA was nine times more abundant than type IV
(type III CIITA was barely detected). Exposure to IFN-
(6 h)
dramatically increased types I and IV CIITA mRNA to similar absolute
levels. Type IV CIITA declined over time, but type I was stable for
over 72 h. Thus, the dominant form of CIITA evolved with time
during activation by IFN-
, and type I CIITA explained prolonged
expression of MHC-II by macrophages. mRNA half-life was shorter for
type I than type IV CIITA, suggesting that sustained transcription
contributed to stable expression of type I CIITA induced by IFN-
.
Splenic B cells expressed mRNA for type III CIITA but very little for
types I or IV. Treatment with IL-4 increased surface expression of
MHC-II protein, but mRNA for MHC-II and CIITA (total, I, III, and IV)
remained unchanged, suggesting posttranslational regulation. Splenic
dendritic cells expressed type I CIITA but little type III or IV; CpG
DNA induced their maturation and decreased types I and III CIITA,
consistent with decreased MHC-II protein synthesis. CIITA types differ
in regulation in various APCs under different stimuli, and the
predominant type of CIITA varies at different stages of APC
activation.
This article has been cited by other articles:
![]() |
M. E. Pennini, Y. Liu, J. Yang, C. M. Croniger, W. H. Boom, and C. V. Harding CCAAT/Enhancer-Binding Protein beta and {delta} Binding to CIITA Promoters Is Associated with the Inhibition of CIITA Expression in Response to Mycobacterium tuberculosis 19-kDa Lipoprotein J. Immunol., November 15, 2007; 179(10): 6910 - 6918. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Herrmann, R. S. Agrawal, S. F. Connolly, R. L. McCaffrey, J. Schlomann, and D. J. Kusner MHC Class II levels and intracellular localization in human dendritic cells are regulated by calmodulin kinase II J. Leukoc. Biol., September 1, 2007; 82(3): 686 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. T. Thieu, E. T. Nguyen, B. P. McCarthy, H. A. Bruns, R. Kapur, C.-H. Chang, and M. H. Kaplan IL-4-stimulated NF-{kappa}B activity is required for Stat6 DNA binding J. Leukoc. Biol., August 1, 2007; 82(2): 370 - 379. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Romieu-Mourez, M. Francois, M.-N. Boivin, J. Stagg, and J. Galipeau Regulation of MHC Class II Expression and Antigen Processing in Murine and Human Mesenchymal Stromal Cells by IFN-{gamma}, TGF-beta, and Cell Density J. Immunol., August 1, 2007; 179(3): 1549 - 1558. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, G. Roderiquez, T. Jones, P. McPhie, and M. A. Norcross Control of In Vitro Immune Responses by Regulatory Oligodeoxynucleotides through Inhibition of pIII Promoter Directed Expression of MHC Class II Transactivator in Human Primary Monocytes J. Immunol., July 1, 2007; 179(1): 45 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhao, E. N. Cha, C. Lee, C. Y. Park, and C. Schindler Stat2-Dependent Regulation of MHC Class II Expression J. Immunol., July 1, 2007; 179(1): 463 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Casals, M. Barrachina, M. Serra, J. Lloberas, and A. Celada Lipopolysaccharide Up-Regulates MHC Class II Expression on Dendritic Cells through an AP-1 Enhancer without Affecting the Levels of CIITA J. Immunol., May 15, 2007; 178(10): 6307 - 6315. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Hastings, R. L. Lackman, and P. Cresswell Functional Requirements for the Lysosomal Thiol Reductase GILT in MHC Class II-Restricted Antigen Processing J. Immunol., December 15, 2006; 177(12): 8569 - 8577. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Green, H. Yoon, and J. M. Boss Epigenetic Regulation during B Cell Differentiation Controls CIITA Promoter Accessibility J. Immunol., September 15, 2006; 177(6): 3865 - 3873. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yao, Q. Xu, M.-J. Kwon, R. Matta, Y. Liu, S.-C. Hong, and C.-H. Chang ERK and p38 MAPK Signaling Pathways Negatively Regulate CIITA Gene Expression in Dendritic Cells and Macrophages J. Immunol., July 1, 2006; 177(1): 70 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Pennini, R. K. Pai, D. C. Schultz, W. H. Boom, and C. V. Harding Mycobacterium tuberculosis 19-kDa Lipoprotein Inhibits IFN-{gamma}-Induced Chromatin Remodeling of MHC2TA by TLR2 and MAPK Signaling J. Immunol., April 1, 2006; 176(7): 4323 - 4330. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shang and T. B. Tomasi The Heat Shock Protein 90-CDC37 Chaperone Complex Is Required for Signaling by Types I and II Interferons J. Biol. Chem., January 27, 2006; 281(4): 1876 - 1884. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-D. Chou, A. N. H. Khan, W. J. Magner, and T. B. Tomasi Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells Int. Immunol., November 1, 2005; 17(11): 1483 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kuchtey, P. J. Chefalo, R. C. Gray, L. Ramachandra, and C. V. Harding Enhancement of Dendritic Cell Antigen Cross-Presentation by CpG DNA Involves Type I IFN and Stabilization of Class I MHC mRNA J. Immunol., August 15, 2005; 175(4): 2244 - 2251. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Chang, J. J. Linderman, and D. E. Kirschner Multiple mechanisms allow Mycobacterium tuberculosis to continuously inhibit MHC class II-mediated antigen presentation by macrophages PNAS, March 22, 2005; 102(12): 4530 - 4535. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. K. Yee, Y. Yao, Q. Xu, B. McCarthy, D. Sun-Lin, M. Tone, H. Waldmann, and C.-H. Chang Enhanced Production of IL-10 by Dendritic Cells Deficient in CIITA J. Immunol., February 1, 2005; 174(3): 1222 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. van der Stoep, E. Quinten, M. M. Rezende, and P. J. van den Elsen E47, IRF-4, and PU.1 synergize to induce B-cell-specific activation of the class II transactivator promoter III (CIITA-PIII) Blood, November 1, 2004; 104(9): 2849 - 2857. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Popkin, M. A. Watson, E. Karaskov, G. P. Dunn, R. Bremner, and H. W. Virgin IV Murine cytomegalovirus paralyzes macrophages by blocking IFN{gamma}-induced promoter assembly PNAS, November 25, 2003; 100(24): 14309 - 14314. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Nagabhushanam, A. Solache, L.-M. Ting, C. J. Escaron, J. Y. Zhang, and J. D. Ernst Innate Inhibition of Adaptive Immunity: Mycobacterium tuberculosis-Induced IL-6 Inhibits Macrophage Responses to IFN-{gamma} J. Immunol., November 1, 2003; 171(9): 4750 - 4757. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Giroux, M. Schmidt, and A. Descoteaux IFN-{gamma}-Induced MHC Class II Expression: Transactivation of Class II Transactivator Promoter IV by IFN Regulatory Factor-1 is Regulated by Protein Kinase C-{alpha} J. Immunol., October 15, 2003; 171(8): 4187 - 4194. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kuchtey, M. Pennini, R. K. Pai, and C. V. Harding CpG DNA Induces a Class II Transactivator-Independent Increase in Class II MHC by Stabilizing Class II MHC mRNA in B Lymphocytes J. Immunol., September 1, 2003; 171(5): 2320 - 2325. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. C. Hornell, G. W. Beresford, A. Bushey, J. M. Boss, and E. D. Mellins Regulation of the Class II MHC Pathway in Primary Human Monocytes by Granulocyte-Macrophage Colony-Stimulating Factor J. Immunol., September 1, 2003; 171(5): 2374 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Pai, M. Convery, T. A. Hamilton, W. H. Boom, and C. V. Harding Inhibition of IFN-{gamma}-Induced Class II Transactivator Expression by a 19-kDa Lipoprotein from Mycobacterium tuberculosis: A Potential Mechanism for Immune Evasion J. Immunol., July 1, 2003; 171(1): 175 - 184. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |